Hemophagocytic syndrome in adults: Recent developments in 2003;Syndrome d'activation macrophagique de l'adulte: État des connaissances en 2003

Sang Thrombose Vaisseaux

Volumn 15, Issue 3, 2003, Pages 135-142

  Larroche, Claire ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BLOOD SMEAR; GENE TECHNOLOGY; HEMOPHAGOCYTIC SYNDROME; HUMAN; INCIDENCE; MACROPHAGE ACTIVATION; PREVALENCE; PROGNOSIS; REVIEW;

EID: 0037695987     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol 1997; 66: 135-151.
2. Blanche S, Caniglia M, Girault D, Landman J, Griscelli C, Fischer A. Treatment of hemophagocytic lymphohistiocytosis with chemotherapy and bone marrow transplantation: a single-center study of 22 cases. Blood 1991; 78: 51-54.
3. Henter JI, Arico M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998; 12: 417-33.
4. Clementi R, Emmi L, Maccario R, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood 2002; 100: 2266-7.
5. Karim MA, Suzuki K, Fukai K, et al. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. Am J Med Genet 2002; 108: 16-22.
6. Sanal O, Ersoy F, Tezcan I, et al. Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity. J Clin Immunol 2002; 22: 237-243.
7. Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br J Haematol 2002; 119: 585-95.
8. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-9.
9. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000; 96: 3118-25.
10. Reiner AP, Spivak JL. Hematophagic histiocytosis. Medicine 1988; 67: 369-88.
11. Stephan F, Thioliere E, Verdy E, Tulliez M. Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis 1997; 25: 1159-64.
12. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993-1002.
13. Albert A, Azgui Z, Buisine J, et al. Macrophage activation syndromes. Nottv Rev Fr Hematol 1992; 34: 435-41.
14. Wong KF, Chan JK. Reactive hemophagocytic syndrome: a clinicopathologic study of 40 patients in an Oriental population. Am J Med 1992; 93: 177-80.
15. Tiab M, Mechinaud F, Hamidou M, Gaillard F, Raffi F, Harousseau JL. Hemophagocytic syndromes. A series of 23 cases. Ann Med Interne 1996; 147: 138-44.
16. Sailler L, Duchayne E, Marchou B, et al. Etiological aspects of reactive hemophagocytoses: retrospective study in 99 patients. Rev Med Interne 1997; 18: 855-64.
17. Tsuda H. Hemophagocytic syndrome in children and adults. Int J Hematol 1997; 65: 215-26.
18. Kaito K, Kobayashi M, Katayama T, et al. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 1997; 59: 247-53.
19. De Kerguenec C, Hillaire S, Molinie V, et al. Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol 2001; 96: 852-7.
20. Emmenegger U, Reimers A, Frey U, et al. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002; 132: 230-6.
21. Marton PF. Erythrophagocytosis in the human bone marrow as disclosed by iliacal bone biopsies. Scand J Haematol 1975; 14: 153-9.
22. Ost A, Nilsson-Ardnor S, Henter JI. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology 1998; 32: 310-6.
23. Henter JI, Arico M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 1997; 28: 342-7.
24. Takahashi N, Chubachi A, Kume M, et al. A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol 2001; 74: 209-13.
25. Larroche C, Bruneel F, Andre MH, et al. Les immunoglobulines intraveineuses dans les syndromes d'activation macrophagique secondaires: étude multicentrique évaluant leur intérêt, pour le groupe d'experts sur les immunoglobulines du CEDIT de l'AP-HP. Ann Med Interne 2000; 151: 533-9.
26. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 2665-73.
27. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46: 1171-6.
28. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol 2001; 7: 252-6.